Multi Cancer Early Detection Testing Market Size
The global Multi Cancer Early Detection Testing Market reached US$ 2.24 billion in 2025 and is expected to reach US$ 10.22 billion by 2033, growing at a CAGR of 16.5% during the forecast period 2026-2033.
The global multi-cancer early detection (MCED) testing market is experiencing rapid growth due to the growing global cancer burden and demand for accurate, non-invasive diagnostic solutions. Technological advancements in liquid biopsy, genomics, and AI-driven bioinformatics enable multiple cancer detection from a single blood sample, improving patient outcomes and survival rates. Despite challenges like high testing costs, limited regulatory approvals, and false positives, MCED presents significant opportunities in emerging markets, strategic collaborations, and precision oncology.
Executive Summary
Multi Cancer Early Detection Testing Market Dynamics: Drivers & Restraints
Driver: Rising Global Cancer Prevalence
The global cancer prevalence is driving the multi-cancer early detection (MCED) testing market, as it provides effective and comprehensive screening solutions. Healthcare systems prioritize early detection to improve survival rates and reduce treatment costs. MCED tests, such as liquid biopsy, offer the advantage of identifying multiple cancers at early stages, addressing the growing demand for efficient screening. This trend is driving the adoption and expansion of MCED technologies globally.
Restraint: Improving Sensitivity and Specificity
Current MCED tests need improvement, particularly for stage I cancer detection. Novel biomarkers and technologies like cfDNA methylation patterns and miRNAs, ultrasensitive sequencing, and PCR can increase sensitivity. Understanding the causes of false positives in healthy individuals and addressing physiological changes like aging, lifestyle habits, and inflammation is crucial for cancer-related biomarker effects.
Multi Cancer Early Detection Testing Market Segment Analysis
The global multi cancer early detection testing market is segmented based on test type, cancer type, end user, and region.
Test Type:
The galleri test segment the expected to have 40.66% of the multi cancer early detection testing market share.
The Galleri test, developed by GRAIL, is a highly advanced blood-based screening solution for cancer detection. It uses next-generation sequencing and methylation pattern analysis to detect over 50 types of cancer from a single blood draw, often early before symptoms appear. Galleri's strong clinical validation, partnerships with healthcare providers, and integration into large-scale screening programs drive market adoption and accelerate the shift towards proactive and precision oncology.
For instance, GRAIL, a healthcare company, and Quest Diagnostics have announced a program to enhance provider access to GRAIL's Galleri multi-cancer early detection (MCED) test. The initial phase of the program allows providers to order the test directly from GRAIL through the Quest Diagnostics connectivity system. This system allows providers in the US to order and receive laboratory test reports electronically through Quest's Quanum laboratory portal and over 900 electronic health record (EHR) systems.
Multi Cancer Early Detection Testing Market Major Key Players
The major players in the multi cancer early detection testing market include GRAIL, Guardant Health, Exact Sciences , Burning Rock Biotech, Lucence Health, Foundation Medicine (Roche), AnchorDx, Freenome, and Niramai among others.
Recent Developments
- April 2026 – GRAIL expands Galleri commercialization and health system partnerships
GRAIL strengthened U.S. commercialization of its Galleri multi-cancer early detection (MCED) blood test through expanded partnerships with healthcare providers and employer health programs aimed at improving population cancer screening adoption. - April 2026 – Guardant Health advances Shield and multi-cancer screening platform development
Guardant Health announced continued expansion of its blood-based cancer screening portfolio, including broader clinical validation activities for multi-cancer detection technologies and AI-driven liquid biopsy analytics. - March 2026 – Exact Sciences strengthens oncology screening pipeline with AI-enabled diagnostics
Exact Sciences expanded development of next-generation MCED technologies integrating genomic analysis and AI-powered biomarker interpretation to improve early cancer detection accuracy across multiple tumor types. - March 2026 – Roche’s Foundation Medicine advances comprehensive genomic profiling for early cancer detection
Foundation Medicine expanded collaborations focused on blood-based genomic profiling and precision oncology diagnostics supporting earlier cancer detection and personalized screening strategies. - February 2026 – Freenome progresses AI-powered blood testing platform for early cancer screening
Freenome advanced clinical validation of its multiomics blood testing platform using AI and machine learning to identify early cancer signals and improve non-invasive screening performance. - February 2026 – Burning Rock Biotech expands pan-cancer liquid biopsy research initiatives
Burning Rock Biotech strengthened development of blood-based early cancer detection technologies through expanded clinical research programs and AI-enabled genomic analysis capabilities in Asia-Pacific markets. - January 2026 – Lucence launches enhanced liquid biopsy solutions for early-stage cancer detection
Lucence Health introduced upgraded ctDNA-based liquid biopsy testing solutions focused on improving sensitivity for early-stage cancer detection and monitoring across multiple cancer indications.
Report Scope
Metrics | Details | |
CAGR | 16.5% | |
Market Size Available for Years | 2022-2033 | |
Estimation Forecast Period | 2026-2033 | |
Revenue Units | Value (US$ Bn) | |
Segments Covered | Test Type | Galleri Test, CancerSEEK, Others |
Cancer Type | Breast Cancer, Colorectal Cancer, Lung Cancer, Blood Cancer, Prostate Cancer and others. | |
| End User | Hospitals & Clinics, Diagnostic Laboratories, Academic & Research Institutes |
Regions Covered | North America, Europe, Asia-Pacific, South America, and the Middle East & Africa | |
The global multi cancer early detection testing market report delivers a detailed analysis with 70 key tables, more than 61 visually impactful figures, and 195 pages of expert insights, providing a complete view of the market landscape.
Suggestions for Related Report
